Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT.

Abstract:

:Medulloblastomas are the most common malignant tumors of the central nervous system during childhood. Radiation-induced medulloblastoma tumor recurrences are aggressive and metastatic in nature. In the present study, we demonstrate that Gadd45a expression can sensitize medulloblastoma cells to radiotherapy. We have elucidated the role of Gadd45a in ionizing radiation (IR)-induced G2-M arrest and invasion and metastatic potential of the medulloblastoma cancer cell lines DAOY and D283. We demonstrate that Gadd45a is induced by IR and results in p53 phosphorylation. The role of IR-induced Gadd45a in G2-M arrest is demonstrated by fluorescence-activated cell sorting analysis in the cells treated with siRNA Gadd45a and Ov-exp Gadd45a. We show that Ov-exp Gadd45a aggravates G2-M blockage and also increases binding of Gadd45a to Cdc2 by immunocytochemistry analysis. Furthermore, we show the anti-tumorigenic role of Gadd45a to be mediated by the negative regulation of IR-induced cancer cell invasion and migration-associated proteins, such as matrix metallopeptidase (MMP)-9 and β-catenin. When compared with IR treatment alone, Ov-exp Gadd45a plus IR treatment resulted in decreased nuclear localization and increased membrane localization of β-catenin, and this was further confirmed by membrane distribution. We also show that Ov-exp Gadd45a resulted in downregulation of MMP-9 and suppression of epithelial-mesenchymal transition (EMT). Alternatively, inhibition of MMP-9 (pM) resulted in upregulation of Gadd45a and suppression of EMT. The anti-tumor effect of pM was correlated with increased expression of Gadd45a protein in nude mice intracranial tumors. Taken together, our studies demonstrate that upregulation of Gadd45a or suppression of MMP-9 (pM) with IR retards medulloblastoma tumor metastatic potential.

journal_name

Neuro Oncol

journal_title

Neuro-oncology

authors

Asuthkar S,Nalla AK,Gondi CS,Dinh DH,Gujrati M,Mohanam S,Rao JS

doi

10.1093/neuonc/nor109

subject

Has Abstract

pub_date

2011-10-01 00:00:00

pages

1059-73

issue

10

eissn

1522-8517

issn

1523-5866

pii

nor109

journal_volume

13

pub_type

杂志文章
  • Late relapse in primary central nervous system lymphoma: clonal persistence.

    abstract::Recurrence of primary central nervous system lymphoma (PCNSL) after initial diagnosis and treatment occurs within 2 years in most patients, and relapse after 5 years is rare. We evaluated late relapse in our PCNSL population. We identified 10 patients from our database of 378 patients (268 achieved a complete response...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor014

    authors: Nayak L,Hedvat C,Rosenblum MK,Abrey LE,DeAngelis LM

    更新日期:2011-05-01 00:00:00

  • Brain metastases in melanoma: roles of neurotrophins.

    abstract::Brain metastasis, which occurs in 20% to 40% of all cancer patients, is an important cause of neoplastic morbidity and mortality. Successful invasion into the brain by tumor cells must include attachment to microvessel endothelial cells, penetration through the blood-brain barrier, and, of relevance, a response to bra...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/s115285170300067x

    authors: Denkins Y,Reiland J,Roy M,Sinnappah-Kang ND,Galjour J,Murry BP,Blust J,Aucoin R,Marchetti D

    更新日期:2004-04-01 00:00:00

  • A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

    abstract::The 2007 World Health Organization (WHO) classification of brain tumors did not use molecular abnormalities as diagnostic criteria. Studies have shown that genotyping allows a better prognostic classification of diffuse glioma with improved treatment selection. This has resulted in a major revision of the WHO classifi...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now277

    authors: van den Bent MJ,Weller M,Wen PY,Kros JM,Aldape K,Chang S

    更新日期:2017-05-01 00:00:00

  • The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

    abstract:BACKGROUND:Genetic and epigenetic profiling of glioblastomas has provided a comprehensive list of altered cancer genes of which only O(6)-methylguanine-methyltransferase (MGMT) methylation is used thus far as a predictive marker in a clinical setting. We investigated the prognostic significance of genetic and epigeneti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou005

    authors: Molenaar RJ,Verbaan D,Lamba S,Zanon C,Jeuken JW,Boots-Sprenger SH,Wesseling P,Hulsebos TJ,Troost D,van Tilborg AA,Leenstra S,Vandertop WP,Bardelli A,van Noorden CJ,Bleeker FE

    更新日期:2014-09-01 00:00:00

  • Protein kinase D2 is a novel regulator of glioblastoma growth and tumor formation.

    abstract::Glioblastoma multiforme, a highly aggressive tumor of the central nervous system, has a dismal prognosis that is due in part to its resistance to radio- and chemotherapy. The protein kinase C (PKC) family of serine threonine kinases has been implicated in the formation and proliferation of glioblastoma multiforme. Mem...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor084

    authors: Azoitei N,Kleger A,Schoo N,Thal DR,Brunner C,Pusapati GV,Filatova A,Genze F,Möller P,Acker T,Kuefer R,Van Lint J,Baust H,Adler G,Seufferlein T

    更新日期:2011-07-01 00:00:00

  • Akt2 and Akt3 play a pivotal role in malignant gliomas.

    abstract::Akt, one of the major downstream effectors of phosphatidylinositol 3-kinase, is hyper-expressed and activated in a variety of cancers including glioblastoma. However, the expression profiles of the Akt isoforms Akt1/PKBalpha, Akt2/PKBbeta, and Akt3/PKBgamma and their functional roles in malignant glioma are not well u...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nop026

    authors: Mure H,Matsuzaki K,Kitazato KT,Mizobuchi Y,Kuwayama K,Kageji T,Nagahiro S

    更新日期:2010-03-01 00:00:00

  • New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach.

    abstract::Diffuse low-grade glioma grows, migrates along white matter tracts, and progresses to high-grade glioma. Rather than a "wait and see" policy, an aggressive attitude is now recommended, with early surgery as the first therapy. Intraoperative mapping, with maximal resection according to functional boundaries, is associa...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou153

    authors: Duffau H,Taillandier L

    更新日期:2015-03-01 00:00:00

  • ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

    abstract::Vestibular schwannomas (VS) arising sporadically or in patients with neurofibromatosis type 2 (NF2) consistently lack expression of Merlin, a tumor suppressor. Conventional treatment options include surgery and radiotherapy but there is no validated medical option. Recent evidence suggests that Merlin deficiency may r...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq012

    authors: Ammoun S,Cunliffe CH,Allen JC,Chiriboga L,Giancotti FG,Zagzag D,Hanemann CO,Karajannis MA

    更新日期:2010-08-01 00:00:00

  • APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

    abstract::Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq176

    authors: Eisele G,Roth P,Hasenbach K,Aulwurm S,Wolpert F,Tabatabai G,Wick W,Weller M

    更新日期:2011-02-01 00:00:00

  • Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

    abstract::The objective of this study was to evaluate whether longitudinal levels of serum YKL-40 correlate with disease status or survival in adults with gliomas. Patients with histologically confirmed gliomas were eligible for this longitudinal study. Serum samples were collected prospectively and concurrently with MRI scans ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nor117

    authors: Iwamoto FM,Hottinger AF,Karimi S,Riedel E,Dantis J,Jahdi M,Panageas KS,Lassman AB,Abrey LE,Fleisher M,DeAngelis LM,Holland EC,Hormigo A

    更新日期:2011-11-01 00:00:00

  • The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

    abstract:Background:There have been few treatment advances for patients with glioblastoma (GBM) despite increasing scientific understanding of the disease. While factors such as intrinsic tumor biology and drug delivery are challenges to developing efficacious therapies, it is unclear whether the current clinical trial landscap...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,meta分析

    doi:10.1093/neuonc/noy027

    authors: Vanderbeek AM,Rahman R,Fell G,Ventz S,Chen T,Redd R,Parmigiani G,Cloughesy TF,Wen PY,Trippa L,Alexander BM

    更新日期:2018-07-05 00:00:00

  • Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.

    abstract:BACKGROUND:Previous pilot studies have shown the feasibility of preoperative chemotherapy in patients with medulloblastoma, but benefits and risks compared with initial surgery have not been assessed. METHODS:Two therapeutic strategies were retrospectively compared in 92 patients with metastatic medulloblastoma treate...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa083

    authors: Guerrini-Rousseau L,Abbas R,Huybrechts S,Kieffer-Renaux V,Puget S,Andreiuolo F,Beccaria K,Blauwblomme T,Bolle S,Dhermain F,Longaud Valès A,Roujeau T,Sainte-Rose C,Tauziede-Espariat A,Varlet P,Zerah M,Valteau-Couanet D,D

    更新日期:2020-11-26 00:00:00

  • Biology and management of ependymomas.

    abstract::Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/now016

    authors: Wu J,Armstrong TS,Gilbert MR

    更新日期:2016-07-01 00:00:00

  • Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics.

    abstract:BACKGROUND:Assessment of treatment response by measuring tumor size is known to be a late and potentially confounded response index. Serial diffusion MRI has shown potential for allowing earlier and possibly more reliable response assessment in adult patients, with limited experience in clinical settings and in pediatr...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/not034

    authors: Rodriguez Gutierrez D,Manita M,Jaspan T,Dineen RA,Grundy RG,Auer DP

    更新日期:2013-08-01 00:00:00

  • Prospective study of cigarette smoking and adult glioma: dosage, duration, and latency.

    abstract::Tobacco products are major contributors of exogenous N-nitroso compounds, a group of potent neurocarcinogens. Overall results from studies of smoking and brain tumors have been null, but have provided little information on duration, age at smoking initiation, and latency. We prospectively examined the relation between...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-005

    authors: Holick CN,Giovannucci EL,Rosner B,Stampfer MJ,Michaud DS

    更新日期:2007-07-01 00:00:00

  • In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

    abstract::Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid derivative, pivaloyloxymethyl butyrate (AN-9), for the treatment of gliomas. Relative to control and single-modality treatments, the combination of AN-9 and radiation significantly inhibited t...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2006-032

    authors: Entin-Meer M,Yang X,VandenBerg SR,Lamborn KR,Nudelman A,Rephaeli A,Haas-Kogan DA

    更新日期:2007-04-01 00:00:00

  • On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

    abstract:BACKGROUND:Glioblastoma multiforme (GBM) is characterized by an aggressive clinical course, therapeutic resistance, and striking molecular heterogeneity. GBM-derived brain tumor stem cells (BTSCs) closely model this molecular heterogeneity and likely have a key role in tumor recurrence and therapeutic resistance. Emerg...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos302

    authors: Stechishin OD,Luchman HA,Ruan Y,Blough MD,Nguyen SA,Kelly JJ,Cairncross JG,Weiss S

    更新日期:2013-02-01 00:00:00

  • Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.

    abstract::Protein kinase C alpha (PKC-alpha) is a cytoplasmic serine threonine kinase involved in regulating cell differentiation and proliferation. Aprinocarsen is an antisense oligonucleotide against PKC-alpha that reduces PKC-alphain human cell lines and inhibits a human glioblastoma tumor cell line in athymic mice. In this ...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/S1152851703000353

    authors: Grossman SA,Alavi JB,Supko JG,Carson KA,Priet R,Dorr FA,Grundy JS,Holmlund JT

    更新日期:2005-01-01 00:00:00

  • Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

    abstract::Angiogenesis is necessary for tumor growth beyond a volume of approximately 2 mm(3). This observation, along with the accessibility of tumor vessels to therapeutic targeting, has resulted in a research focus on inhibitors of angiogenesis. A number of endogenous inhibitors of angiogenesis are found in the body. Some of...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1215/S115285170400119X

    authors: Rege TA,Fears CY,Gladson CL

    更新日期:2005-04-01 00:00:00

  • A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

    abstract:BACKGROUND:Both the epidermal growth factor receptor and vascular endothelial growth factor pathways are frequently overexpressed in glioblastoma multiforme. This study combined bevacizumab, a vascular endothelial growth factor inhibitor, and erlotinib, an epidermal growth factor receptor inhibitor, with standard radia...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nou029

    authors: Clarke JL,Molinaro AM,Phillips JJ,Butowski NA,Chang SM,Perry A,Costello JF,DeSilva AA,Rabbitt JE,Prados MD

    更新日期:2014-07-01 00:00:00

  • PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.

    abstract:BACKGROUND:Temozolomide (TMZ) resistance in Glioblastoma (GBM) is mediated by the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). MGMT promoter methylation (occurs in about 40% patients) is associated with loss of MGMT expression (MGMT-) that compromises DNA repair, leading to a favorable response to ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noab003

    authors: Wu S,Li X,Gao F,de Groot JF,Koul D,Yung WKA

    更新日期:2021-01-12 00:00:00

  • Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

    abstract::Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria...

    journal_title:Neuro-oncology

    pub_type: 临床试验,杂志文章

    doi:10.1215/15228517-2007-044

    authors: Stelzer KJ,Douglas JG,Mankoff DA,Silbergeld DL,Krohn KA,Laramore GE,Spence AM

    更新日期:2008-02-01 00:00:00

  • Convection-enhanced delivery for the treatment of glioblastoma.

    abstract::Effective treatment of glioblastoma (GBM) remains a formidable challenge. Survival rates remain poor despite decades of clinical trials of conventional and novel, biologically targeted therapeutics. There is considerable evidence that most of these therapeutics do not reach their targets in the brain when administered...

    journal_title:Neuro-oncology

    pub_type: 杂志文章,评审

    doi:10.1093/neuonc/nou354

    authors: Vogelbaum MA,Aghi MK

    更新日期:2015-03-01 00:00:00

  • Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma.

    abstract::Although external beam radiation is an essential component to the current standard treatment of primary brain tumors, its application is limited by toxicity at doses more than 80 Gy. Recent studies have suggested that brachytherapy with liposomally encapsulated radionuclides may be of benefit, and we have reported met...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos060

    authors: Phillips WT,Goins B,Bao A,Vargas D,Guttierez JE,Trevino A,Miller JR,Henry J,Zuniga R,Vecil G,Brenner AJ

    更新日期:2012-04-01 00:00:00

  • Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007.

    abstract:Background:Previous reports have shown that overall incidence of malignant brain and other central nervous system (CNS) tumors varied significantly by country. The aim of this study was to estimate histology-specific incidence rates by global region and assess incidence variation by histology and age. Methods:Using da...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nox091

    authors: Leece R,Xu J,Ostrom QT,Chen Y,Kruchko C,Barnholtz-Sloan JS

    更新日期:2017-10-19 00:00:00

  • Predictors of leptomeningeal disease following hypofractionated stereotactic radiotherapy for intact and resected brain metastases.

    abstract:BACKGROUND:The objective was to evaluate the risk and predictors of developing leptomeningeal disease (LMD) in patients with brain metastases treated with 5-fraction hypofractionated stereotactic radiotherapy (HSRT). METHODS:Patients treated with HSRT for intact brain metastases and/or surgical cavities were reviewed ...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noz144

    authors: Nguyen TK,Sahgal A,Detsky J,Atenafu EG,Myrehaug S,Tseng CL,Husain Z,Heyn C,Maralani P,Ruschin M,Perry J,Soliman H

    更新日期:2020-01-11 00:00:00

  • Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.

    abstract::Identification of the epidermal growth factor receptor variant III (EGFRvIII) mutation in glioblastoma has become increasingly relevant in the optimization of therapy. Traditionally, determination of tumor EGFRvIII-expression has relied on tissue-based diagnostics. Here, we assess the accuracy of magnetic resonance pe...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/nos073

    authors: Tykocinski ES,Grant RA,Kapoor GS,Krejza J,Bohman LE,Gocke TA,Chawla S,Halpern CH,Lopinto J,Melhem ER,O'Rourke DM

    更新日期:2012-05-01 00:00:00

  • Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas.

    abstract::The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal. Understanding the potential behavior of these tumors in individual patients is critical for rational therapeuti...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noq081

    authors: Pérez-Magán E,Rodríguez de Lope A,Ribalta T,Ruano Y,Campos-Martín Y,Pérez-Bautista G,García JF,García-Claver A,Fiaño C,Hernández-Moneo JL,Mollejo M,Meléndez B

    更新日期:2010-12-01 00:00:00

  • Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

    abstract:BACKGROUND:Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular s...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1093/neuonc/noaa117

    authors: Eckel-Passow JE,Drucker KL,Kollmeyer TM,Kosel ML,Decker PA,Molinaro AM,Rice T,Praska CE,Clark L,Caron A,Abyzov A,Batzler A,Song JS,Pekmezci M,Hansen HM,McCoy LS,Bracci PM,Wiemels J,Wiencke JK,Francis S,Burns TC,

    更新日期:2020-11-26 00:00:00

  • Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

    abstract::The effects of combining histone deacetylase (HDAC) inhibitors and proteasome inhibitors were evaluated in both established glioblastoma multiforme (GBM) cell lines and short-term cultures derived from the Mayo Clinic xenograft GBM panel. Coexposure of LBH589 and bortezomib at minimally toxic doses of either drug alon...

    journal_title:Neuro-oncology

    pub_type: 杂志文章

    doi:10.1215/15228517-2007-063

    authors: Yu C,Friday BB,Yang L,Atadja P,Wigle D,Sarkaria J,Adjei AA

    更新日期:2008-06-01 00:00:00